Related projects
Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
Adiga Life Sciences Inc. developed a novel immunotherapeutic platform in which small components (peptides) of allergen proteins are identified and administered in a regimen that causes immune cells to become non-responsive towards the allergens. In a phase II clinical trial, the cat allergy treatment developed by Adiga using this platform reduced allergic symptoms in allergic subjects. However, the mechanism of action of the peptide treatment is still not fully understood. During this project, relevant peptides from dog allergens will be identified and assessed for the ability to ameliorate dog allergy. In addition, samples collected from the clinical trials will be assessed to identify how the treatment works and affects immune cells. This project will therefore lead to the production of a new allergen immunotherapeutic and identify a mechanism(s) of action. This will increase our understanding of immunotherapy and potentially identify new targets and biomarkers for the treatment of allergic diseases.
Mark Larche
Rebekah Sherburn
Adiga Life Science Inc.
Medicine
Life sciences
McMaster University
Elevate
Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
Find the perfect opportunity to put your academic skills and knowledge into practice!
Find ProjectsThe strong support from governments across Canada, international partners, universities, colleges, companies, and community organizations has enabled Mitacs to focus on the core idea that talent and partnerships power innovation — and innovation creates a better future.